Physician profile
Tyler C Argyle
NPI 1043874134
$2,654.14
in general payments reported to CMS, 2019-2025
18 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.74 · 2020: $37.90 · 2022: $156 · 2023: $806 · 2024: $676 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.00 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $599.84 | 2025 | Rapiblyk |
| E.R. Squibb & Sons, L.L.C. | $318.53 | 2022-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $266.70 | 2020-2024 | Xarelto |
| Abbvie INC. | $226.75 | 2024-2025 | |
| Csl Behring | $188.54 | 2023-2025 | Kcentra |
| Pfizer INC. | $160.07 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $153.76 | 2020-2025 | Ultomiris |
| Ferring Pharmaceuticals INC. | $147.89 | 2024-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $103.48 | 2023-2024 | Dificid, Zerbaxa |
| Shionogi INC | $84.94 | 2022-2024 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.57 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.54 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $59.79 | 2022-2023 | Lokelma |
| Vifor Pharma, INC. | $54.97 | 2022-2023 | Veltassa |
| Vertex Pharmaceuticals Incorporated | $44.86 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $35.11 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $35.00 | 2023 | |
| Tetraphase Pharmaceuticals, INC. | $30.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Argyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.